Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial

Abstract

Given evidence of chronic inflammation in bipolar disorder (BD), we tested the efficacy of aspirin and minocycline as augmentation therapy for bipolar depression. Ninety-nine depressed outpatients with BD were enrolled in a 6 week, double-blind, placebo-controlled trial, and randomized to one of four groups: active minocycline (100 mg b.i.d.) + active aspirin (81 mg b.i.d.) (M + A); active minocycline + placebo aspirin (M + P); placebo-minocycline + active aspirin (A + P); and placebo-minocycline + placebo aspirin (P + P). A blinded interim analysis mid-way through the study led to the dropping of the M + P and A + P arms from further enrollment giving numbers per group who were included in the final analysis of: 30 (M + A), 18 (M + P), 19 (A + P), and 28 (P + P). When the study started, there were three primary outcome measures. Based on the results of the interim analysis, the primary outcome variable, response to treatment as defined by >50% decrease in Montgomery–Äsberg Depression Rating Scale (MADRS) score was maintained. The other two (i.e., the change in mean MADRS score from baseline to end of study and the remission rate, with remission being defined as a score of <11 on the MADRS) were reduced to exploratory outcome measures because the interim analysis indicated that the study was adequately powered to test differences in response rate but not the mean change in MADRS scores or remission rates. CRP and IL-6 were assayed to measure inflammation. Urinary thromboxane B2 (11-D-TXB2) concentrations, which were significantly increased at baseline in the combined BD sample (n = 90) vs. a healthy control group (n = 27), served as an indirect marker of cyclooxygenase (COX) activity. In a two-group analysis, the M + A group showed a greater response rate than the P + P group (p(one-tailed) = 0.034, OR = 2.93, NNT = 4.7). When all four arms were included in the analysis, there was a main effect of aspirin on treatment response that was driven by both the M + A and the A + P groups (p(two-tailed) = 0.019, OR = 3.67, NNT = 4.0). Additionally, there was a significant 3-way interaction between aspirin, minocycline, and IL-6, indicating that response to minocycline was significantly greater in participants in the M + P group with higher IL-6 concentrations. Further, participants in the M + P group who responded to treatment had significantly greater decreases in IL-6 levels between baseline and visit 7 vs. non-responders. Regarding the exploratory outcomes, there was a main effect for aspirin on the remission rate (χ12 = 4.14, p(2t) = 0.04, OR = 2.52, NNT = 8.0). There was no significant main effect of aspirin or minocycline on the mean change in MADRS score across visits. Aspirin and minocycline may be efficacious adjunctive treatments for bipolar depression. Given their potential import, additional studies to confirm and extend these findings are warranted.

New drug candidates for bipolar disorder—A nation‐wide population‐based study

“…The inhibition of COX‐1 is neuroprotective based on preclinical evidence while COX‐2 inhibition increases leukocyte recruitment into the brain exacerbating tissue damage . A pilot randomized trial suggests that aspirin might impact bipolar depression …”

Bipolar Spectrum Disorder May Be Associated With Family History of Diseases

“…They are responsible for the production of cytokines and chemokines, referred to as innate immunity. They are located in the microglia, thyroid gland, adrenal gland, intestines and for a certain developmental period in the thymus gland [13]. At this point, it is important to remember that the first term designating mood stabilizing agents was thymoleptics.…”

Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT

“…Any suggestion that the present study missed microglial activation because PET TSPO binding does not detect it or that minocycline is ineffective against it would be premature in the light of recent studies in depression. Two studies 76,77 reported increased PET TSPO binding in patients with major depressive disorder, and a further two studies 78,79 reported that minocycline substantially reduced depression in treatment-resistant patients 78 and in a sample of patients with bipolar depression. 79 This suggests that fundamental differences may exist between the immune basis of psychosis and that of depression.…”